https://retacompare.com/news/celltrion-s-new-obesity-drug-shows-promise-in-preclinical-study 2026-11-04T01:48:29.000Z RetatrutideCompare en 2026-11-04T01:48:29.000Z Celltrion's New Obesity Drug Shows Promise in Preclinical Study Clinical Trials, Retatrutide https://retacompare.com/news/celltrion-s-new-obesity-drug-shows-promise-against-retatrutide 2026-11-04T01:10:39.000Z RetatrutideCompare en 2026-11-04T01:10:39.000Z Celltrion's New Obesity Drug Shows Promise Against Retatrutide Market News, Retatrutide https://retacompare.com/news/glp-1-agonists-show-superior-benefits-over-metformin-in-prediabetes-management 2026-11-03T20:06:09.000Z RetatrutideCompare en 2026-11-03T20:06:09.000Z GLP-1 Agonists Show Superior Benefits Over Metformin in Prediabetes Management Clinical Trials, Retatrutide https://retacompare.com/news/concerns-over-prescribing-compounded-glp-1-agonists-highlighted 2026-11-03T19:23:07.000Z RetatrutideCompare en 2026-11-03T19:23:07.000Z Concerns Over Prescribing Compounded GLP-1 Agonists Highlighted Market News, Retatrutide https://retacompare.com/news/uconn-health-explores-advances-in-glp-1-agonists 2026-11-03T15:37:27.000Z RetatrutideCompare en 2026-11-03T15:37:27.000Z UConn Health Explores Advances in GLP-1 Agonists Market News, Retatrutide https://retacompare.com/news/bariatric-surgery-effective-after-glp-1-drug-intolerance-study-shows 2026-11-03T14:11:36.000Z RetatrutideCompare en 2026-11-03T14:11:36.000Z Bariatric Surgery Effective After GLP-1 Drug Intolerance, Study Shows Weight Loss, Retatrutide https://retacompare.com/news/fda-issues-warnings-on-unapproved-use-of-retatrutide-amid-legislative-action 2026-11-03T13:47:17.000Z RetatrutideCompare en 2026-11-03T13:47:17.000Z FDA Issues Warnings on Unapproved Use of Retatrutide Amid Legislative Action Market News, Retatrutide https://retacompare.com/news/us-off-label-use-of-glp-1s-could-reach-one-million-users 2026-11-03T12:17:09.000Z RetatrutideCompare en 2026-11-03T12:17:09.000Z US Off-Label Use of GLP-1s Could Reach One Million Users Market News, Retatrutide https://retacompare.com/news/hormone-therapy-may-affect-women-s-response-to-glp-1-weight-loss-drugs 2026-11-03T10:20:00.000Z RetatrutideCompare en 2026-11-03T10:20:00.000Z Hormone Therapy May Affect Women's Response to GLP-1 Weight Loss Drugs Weight Loss, Retatrutide https://retacompare.com/news/chinese-firm-develops-electronic-glp-1-to-tackle-obesity 2026-11-03T08:21:26.000Z RetatrutideCompare en 2026-11-03T08:21:26.000Z Chinese Firm Develops 'Electronic' GLP-1 to Tackle Obesity Market News, Retatrutide https://retacompare.com/news/unregulated-retatrutide-product-linked-to-liver-injury-in-case-report-2 2026-11-03T02:19:59.000Z RetatrutideCompare en 2026-11-03T02:19:59.000Z Unregulated Retatrutide Product Linked to Liver Injury in Case Report Patient Experiences, Retatrutide https://retacompare.com/news/unregulated-retatrutide-product-linked-to-liver-injury-in-case-report 2026-11-03T02:19:59.000Z RetatrutideCompare en 2026-11-03T02:19:59.000Z Unregulated Retatrutide Product Linked to Liver Injury in Case Report Patient Experiences, Retatrutide https://retacompare.com/news/glp-1-agonists-role-in-liver-and-cardiovascular-diseases-reviewed 2026-11-03T00:00:00.000Z RetatrutideCompare en 2026-11-03T00:00:00.000Z GLP-1 Agonists' Role in Liver and Cardiovascular Diseases Reviewed Clinical Trials, Retatrutide https://retacompare.com/news/digital-tools-enhance-glp-1-agonist-use-for-obesity-management 2026-11-03T00:00:00.000Z RetatrutideCompare en 2026-11-03T00:00:00.000Z Digital Tools Enhance GLP-1 Agonist Use for Obesity Management Weight Loss, Retatrutide https://retacompare.com/news/study-indicates-reduced-alcohol-consumption-among-glp-1-users 2026-11-02T21:28:49.000Z RetatrutideCompare en 2026-11-02T21:28:49.000Z Study Indicates Reduced Alcohol Consumption Among GLP-1 Users Patient Experiences, Retatrutide